Pharmacogenetic Testing (PGx)

What are the benefits of Pharmacogenetic Testing?

  • Remove the need for the “Trial and Error” method.
  • Drastically reduce the number of hours required to find the correct medication for each patient.
  • Save patients much needed money by eliminating the co-pays of unnecessary medications.
  • Prevent patients from experiencing unwanted adverse events.
  • Decrease the yearly number of patient hospitalizations as a result of drug-gene interactions.

Request Test Kits

Please indicate the quantity of test kits you would like to receive, then proceed to the next page to confirm your shipping and contact information. Please note: complimentary sample kits are only available to licensed medical professionals.

What will a TruGenX Pharmacogenetic Test Reveal?

Pharmacogenetic testing is primarily concerned with variations in enzymes that affect drug metabolism. Cytochrome P450 enzymes, notably CYP2C9, CYP2C19, and CYP2D6 are accountable for approximately 70% of drug metabolism in the body.

Within the human body lies the cytochrome P450 enzymes which are key components of both the synthesis and metabolism of molecules within a cell. These enzymes are particularly needed when breaking down the active ingredients of most medications. Polymorphisms, or the presence of a genetic variation, within the gene of a human may affect the function of the cytochrome P450 enzymes. These variations are broken down into 6 categories based on their expected effect on how a patient will metabolize a drug.

Poor Metabolizer

A patient who will metabolize a drug very slowly creating an accumulation of medication within the body. This slow break down of the drug increases the risk of unwanted side effects even when prescribed a low dose.

Reduced Intermediate Metabolizer

A patient who will metabolize a drug at a reduced rate. This patient may require a lower dose of the medication to avoid unwanted side effects.

Intermediate Metabolizer

A patient who can metabolize a drug at a slower rate than a normal metabolizer and will usually require a lower dose of a medication. This lower dose stops the unmetabolized drug from accruing in the body and causing unwanted side effects.

Normal (Extensive) Metabolizer

A patient who can metabolize a drug at a normal rate and may generally break down standard doses as recommended in the Prescribing Information of the medication.

Rapid Metabolizer

A patient who will metabolize a drug before the body is able to attain the desired effect. A higher dose is typically required in order to reach the expected outcome of the medication.

Ultra-Rapid Metabolizer

A patient who will metabolize a drug even faster than a rapid metabolizer and usually before the body is able to attain the desired effect. A higher dose may also be required in order to reach the expected outcome of the medication.

Recommendation on starting does and, if necessary, possible alternative medications

Color key for TruGenX Pharmacogenetic test

Medications in the green column can be prescribed according to standard regimens or the patient’s risk for the indicated condition is not increased.

Medications in the yellow column indicate that guidelines exist for adjusting dosage, increased vigilance or the patient has a moderate risk of the indicated condition.

Medications in the red column have potentially reduced efficacy, increased toxicity or the patient has an increased risk for the indicated condition

Medication Summary

Cardiac
Therapeutic ClassStandard PrecautionsCaution / InfoChange recommended
AntiarrhythmicsFlecainide
Propafenone
AnticoagulantsAcenocoumarolWarfarin
AnticonvulsantsPhenytoin
Antiplatelet AgentsClopidogrel
Prasugrel
Ticagrelor

Recommendations on starting dose and, if necessary, possible alternative medications

DrugFindingRecommendationConcernEvidence
Antiplatelet Agents
Clopidogrel
FDA Drug Label: Actionable PGx
CYP2C19: Ultra-rapid metabolizerIndividuals with ultrarapid metabolizer status may benefit from the elevated plasma concentration of the active compound when taking a standard dose. They may also be at increased risk of bleeding due to elevated plasma concentrations of the active compound. No additional therapeutic recommendations.Efficacy

Pocket Reference Card

A TruGenX Pharmacogenetics report will reveal how well the genes of a patient will metabolize medications. The patient will be given a pocket reference card to share with each one of their Doctors.

TruGenX pocket reference card

TruGenX currently tests 16 genes to determine how they will affect a medication. Providers can order a Comprehensive Panel, one of the three Subspecialty Panels or create a Custom Panel to meet the needs of the patient.

Phamacogenetic Test Panels
Comprehensive PanelAPOECOMTCYP1A2CYP2C19CYP2C9CYP2D6CYP3A4CYP3A5DPYDHTR2AHTR2CMTHFRVKORC1Factor IIFactor VSLC01B1
Cardiac PanelAPOECYP2C19CYP2C9CYP2D6CYP3A4CYP3A5MTHFRVKORC1Factor IIFactor VSLC01B1
Pysch PanelCOMTCYP1A2CYP2B6CYP2C19CYP2C9CYP2D6CYP3A4CYP3A5DPYDHTR2AHTR2CMTHFR
Pain PanelCOMTCYP1A2CYP2B6CYP2C19CYP2C9CYP2D6CYP3A4CYP3A5
Custom Panel
Choose 1 or several
APOECOMTCYP1A2CYP2C19CYP2C9CYP2D6CYP3A4CYP3A5DPYDHTR2AHTR2CMTHFRVKORC1Factor IIFactor VSLC01B1

It is important to know when to order a Pharmacogenetic test for a patient. There are many reasons why the results of this test will help each patient. This table describes the approved indications to follow when ordering a Pharmacogenetic test.

  When To Order Pharmacogenetic Testing

Medical Necessity
PolypharmacyPatient is currently prescribed 4 or more medications
Adverse ReactionPatient has had to visit a Doctor's office or an Emergency Room as a result of an unwanted reaction to a medication
Resistance or Lack of EfficacyPatient has not received relief from his or her current prescription plan
Personal or Family HistoryPatient has personal or family history of unexpected outcomes from certain medications
Targeted Drug TherapyPatient is a candidate for a targeted drug therapy associated with a specific gene biomarker or gene mutation
FDA Cleared Drug with Genetic GuidanceThe "Indications and Usage" section of the prescribing information stating the identification of the gene biomarker as being clinically necessary prior to initiating therapy
Received less than 5 days of Warfarin TherapyThe results of the Pharmacogenetic test will directly impact clinical decision=making of the initial dose
Clinical Utilization
Guidance in choosing the most effective medicationGenetic inheritance affects an individual's response to a medication. It is possible to predict therapeutic failures or dangerous adverse reactions through Pharmacogenetic testing.
Guidance in choosing the safest medicationDrug toxicity will vary by each patient. Other factors need to be considered such as age, liver function, nutrition, smoking and associated diseases.
Guidance in choosing the initial or titrating doseThe "trial and error" method could lead to fatal consequences and may extend the time to optimum dose. Pharmacogenetic testing will help to choose the right test the first time.
Guidance in minimizing the risk of polypharmacyEach additional medication that is added to a patient's treatment plan increases the risk of adverse events. Knowing how a patient will metabolize the prescribed medication will drastically reduce the risk.
Guidance in managing the patient's thrombotic riskSubstantial findings in the Prescribing Information state that the existence of genetic variations in both the CYP2C9 and VKORC1 will alter the dose response to Warfarin and Clopidogrel

Sample Report

A sample TruGenX report on Pharmacogenetics
Click to View Report

Request Test Kits

Please indicate the quantity of test kits you would like to receive, then proceed to the next page to confirm your shipping and contact information. Please note: complimentary sample kits are only available to licensed medical professionals.